Lundbeckfond Invest A/S 3
3 · Lexeo Therapeutics, Inc. · Filed Nov 2, 2023
Insider Transaction Report
Form 3
Lundbeckfond Invest A/S
10% Owner
Holdings
Series A convertible preferred stock
→ Common Stock (1,321,474 underlying)Series B convertible preferred stock
→ Common Stock (246,883 underlying)
Footnotes (2)
- [F1]Each share of Series A convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F2]Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.